Clinical trial register · Spain

Clinical Trials in Barcelona, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV

Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5875 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC

5875

Studies in scope

all four open statuses

3096

Recruiting now

open to new participants

1137

Lead sponsors

across recruiting studies

Top sites

Barcelona 188 Madrid 183 Seville 71 Málaga 66 Valencia 60

Trials with a site in Barcelona

Status

Study

Lead sponsor

Phase

Enrol

Sites in Spain

Start

Recruiting

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian Cancer

NCT07851025Epithelial Ovarian Cancer

DrugsTorvutatug samrotecan·Bevacizumab

AstraZeneca

Phase 3

950

Barcelona

2026-09-16

Recruiting

A Phase III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With CKD Stage 3b and 4 (BalanceD-CKD)

NCT07624305Renal Insufficiency, Chronic

DrugsBalcinrenone/dapagliflozin·Dapagliflozin

AstraZeneca

Phase 3

2,800

Badajoz, Barcelona, Córdoba, Girona, Madrid, Majadahonda, Talavera de la Reina, Valencia

2026-09-01

Recruiting

Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment

NCT07691970Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

1,072

Barcelona, Castellon, Granada, Las Palmas de Gran Canaria, Madrid, Valencia, Vigo

2026-08-31

Not yet open

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

NCT07735637Newly Diagnosed Multiple Myeloma (NDMM)

DrugsASCT·AZD0120·Melphalan·Lenalidomide

AstraZeneca

Phase 3

750

Badalona, Barcelona, El Palmar, Madrid, Salamanca, Santander, Seville

2026-08-25

Recruiting

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

NCT07761117Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)

DrugElecoglipron

AstraZeneca

Phase 3

6,950

Barcelona, Jaén, Madrid, Murcia, Salamanca, Sanlúcar de Barrameda (Cádiz), Seville, Valencia

2026-08-24

Recruiting

A Study to Investigate Outcomes With Elecoglipron Compared With Placebo in Adult Participants With Chronic Kidney Disease.

NCT07753993Chronic Kidney Disease

DrugElecoglipron

AstraZeneca

Phase 3

7,000

Badajoz, Barcelona, Burgos, Córdoba, Granada, Madrid, Majadahonda, Málaga

2026-08-21

Recruiting

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

NCT07784270Obesity or Overweight, Diabetes Mellitus, Type 2

DrugLenbelintide

AstraZeneca

Phase 3

1,500

A Coruña, Alzira, Barcelona, Ferrol, Lleida, Málaga, Oviedo, Segovia

2026-08-20

Recruiting

A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients.

NCT07619131Hypercholesterolaemia

DrugsRosuvastatin 1·Rosuvastatin 2

AstraZeneca

Phase 3

600

Barcelona, Figueres, La Roca del Vallès, Mataró, Viladecans

2026-08-12

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus

NCT07662044Type 2 Diabetes Mellitus

DrugsElecoglipron·Dapagliflozin

AstraZeneca

Phase 3

800

Barcelona, Figueres, Seville

2026-07-06

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin

NCT07662135Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease

DrugElecoglipron

AstraZeneca

Phase 3

900

Barcelona, Ferrol, Lleida, Madrid, Majadahonda, Málaga, Santander, Seville

2026-07-06

Recruiting

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

NCT07667803Weight Management

DrugElecoglipron

AstraZeneca

Phase 3

4,500

A Coruña, Almería, Badalona, Barcelona, León, Madrid, Santander, Santiago de Compostela

2026-06-29

Recruiting

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

NCT07764978Newly Diagnosed Multiple Myeloma

DrugsAZD0120·Isatuximab·Bortezomib·Daratumumab

AstraZeneca

Phase 3

750

Badalona, Barcelona, Madrid, Pamplona, Salamanca, Seville, Valencia

2026-06-26

Recruiting

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

NCT07647328ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Ribociclib

AstraZeneca

Phase 3

150

Badajoz, Badalona, Barcelona, Burgos, Donostia / San Sebastian, Huelva, Jaén, Las Palmas de Gran Canaria

2026-06-15

Recruiting

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

NCT07652658Idiopathic Pulmonary Fibrosis (IPF)

AstraZeneca

Phase 2

359

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Valencia

2026-06-11

Active, closed

A Study to Evaluate the Efficacy and Safety of Concomitant Use of Eplontersen and ALXN2220 Compared With Eplontersen and Placebo for Adults Participants With ATTR-CM

NCT07608354Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

DrugsCliramitug·Eplontersen

AstraZeneca

Phase 2

326

Barcelona, Jaén, L'Hospitalet de Llobregat, Majadahonda, Málaga, Pamplona, Salamanca, Valencia

2026-06-11

Recruiting

Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab

NCT07024706Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)

DrugsVenclyxto·Acalabrutinib·Venclexta·Venetoclax

AstraZeneca

Phase 2

Barcelona, Granada, Madrid, Majadahonda

2026-06-04

Recruiting

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

NCT07590934Metastatic Prostate Cancer

DrugsAZD2287·FPI-2265·Palacaparib·Docetaxel

AstraZeneca

Phase 1/2

152

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona

2026-06-03

Recruiting

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

NCT07611110Metastatic Castration-resistant Prostate Cancer

DrugsXofigo·FPI-2265·Cabazitaxel·Zytiga

AstraZeneca

Phase 3

670

Barcelona, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Santiago de Compostela

2026-05-04

Recruiting

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

NCT07430306Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

245

Barcelona, Córdoba, Galdakao, Madrid, Sabadell, Santander, Seville, Valencia

2026-04-13

Recruiting

A Study to Assess the Effect of Surovatamig in Adult Participants With Antibody-mediated Kidney Disease

NCT07571746Primary Membranous Nephropathy

DrugSurovatamig

AstraZeneca

Phase 2

Barcelona, Madrid

2026-03-28

Recruiting

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

NCT07446855Solid Tumours

DrugSaruparib

AstraZeneca

Phase 1/2

180

Barcelona, Logroño, Pozuelo de Alarcón, Seville

2026-03-17

Recruiting

A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

NCT07391657Relapsed Refractory Multiple Myeloma

DrugsAZD0120·Darzalex·Velcade·Carfilzomib

AstraZeneca

Phase 3

508

Barcelona, Madrid, Pamplona, Salamanca, Santander, Valencia

2026-02-23

Recruiting

A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.

NCT07215702Sepsis, Acute Kidney Injury

DrugAZD4144

AstraZeneca

Phase 2

124

Barcelona, Jerez de la Frontera, Valencia

2026-02-10

Recruiting

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer

DrugsSonesitatug Vedotin·Zolbetuximab·Rilvegostomig·Leucovorin

AstraZeneca

Phase 3

2,130

Barcelona, Madrid, Pamplona, Santander, Santiago de Compostela, Valencia

2026-02-03

Recruiting

Anifrolumab Malignancy and Serious Infections Study

NCT07000110Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Observational

3,506

Barcelona

2026-01-26

Recruiting

Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT07402915Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal

DrugsTorvutatug samrotecan·Itraconazole

AstraZeneca

Phase 1

Barcelona, Logroño, Madrid

2026-01-26

Recruiting

A Study of AZD0120 in Autoimmune Diseases

NCT07295847Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis

DrugAZD0120

AstraZeneca

Phase 1

Barcelona, Madrid

2026-01-09

Recruiting

AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer

NCT07218809Epithelial Ovarian Cancer

DrugsTorvutatug samrotecan·MIRV·Mirvetuximab Soravtansine·Pegylated liposomal doxorubicin

AstraZeneca

Phase 3

1,100

A Coruña, Badalona, Barcelona, Córdoba, Donostia / San Sebastian, Girona, L'Hospitalet de Llobregat, Madrid

2025-12-29

Recruiting

A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis

NCT07276581Rheumatoid Arthritis

AstraZeneca

Phase 2

320

Barcelona, Málaga, Sabadell, Santiago de Compostela, Valencia

2025-12-15

Recruiting

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

NCT07221253Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab

AstraZeneca

Phase 3

1,100

Barcelona, L'Hospitalet de Llobregat, Madrid, Santander

2025-12-04

Recruiting

Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants

NCT07201558Rheumatoid Arthritis, Systemic Lupus Erythematosus

DrugSurovatamig

AstraZeneca

Phase 1

Barcelona, Córdoba, Madrid

2025-12-02

Recruiting

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

NCT07161414Advanced Solid Tumors

DrugsRecombinant Human Hyaluronidase·Rilvegostomig

AstraZeneca

Phase 1

Barcelona, Madrid

2025-11-25

Recruiting

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

NCT06996782Advanced or Metastatic Non-small Cell Lung Cancer

DrugsRamucirumab·Rilvegostomig·Nab-paclitaxel·Pemetrexed

AstraZeneca

Phase 1/2

152

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón, Valencia

2025-11-24

Recruiting

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

NCT07109219B-cell Acute Lymphoblastic Leukemia (B-ALL)

AstraZeneca

Phase 1/2

Badalona(Barcelona), Barcelona, Salamanca, Santander, Valencia

2025-11-12

Recruiting

A Study to Evaluate the Efficacy, Safety, and PK of AZD0292 Administered IV in Participants 12 Years of Age and Older With Bronchiectasis and Chronic Pseudomonas Aeruginosa Colonization

NCT07088926Bronchiectasis With Pseudomonas Aeruginosa Colonization

DrugAZD0292

AstraZeneca

Phase 2

435

Barcelona, Benalmádena, Madrid, Mérida, Patraix, Valencia

2025-11-06

Recruiting

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

NCT07064122Haematologic Neoplasms

AstraZeneca

Phase 1

Barcelona, Madrid, Pamplona, Salamanca, Valencia

2025-11-03

Recruiting

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

NCT07291037Non-small Cell Lung Cancer (NSCLC)

DrugsDato-DXd·Docetaxel

AstraZeneca

Phase 3

400

A Coruña, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Seville, Zaragoza

2025-10-31

Recruiting

A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer

NCT07205822Breast Cancer

DrugDato-DXd

AstraZeneca

Phase 3

100

A Coruña, Barcelona, Granada, Madrid, Seville, Valencia

2025-10-30

Recruiting

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

NCT07181161Metastatic Prostate Cancer

DrugPalacaparib

AstraZeneca

Phase 1/2

283

Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Santander, Valencia

2025-10-01

Recruiting

A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer

NCT07192614Prostate Cancer

AstraZeneca

Phase 1/2

Barcelona, L'Hospitalet de Llobregat, Madrid

2025-09-30

Active, closed

Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.

NCT06992609Small Cell Lung Carcinoma

DrugDurvalumab

AstraZeneca

Phase 3

A Coruña, Badajoz, Barakaldo, Barcelona, Madrid, Málaga, Oviedo, Santander

2025-09-15

Recruiting

A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain

NCT07029737Mantle-cell Lymphoma

DrugsLisaftoclax·Acalabrutinib

AstraZeneca

Phase 2

A Coruña, Alcorcón, Badalona, Barcelona, Burgos, Donostia / San Sebastian, Gijón, Madrid

2025-09-05

Recruiting

A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism

NCT07007793Primary Hyperaldosteronism

DrugBaxdrostat

AstraZeneca

Phase 3

250

Barcelona, Madrid, Seville

2025-08-07

Recruiting

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

NCT06952803Prostate Cancer

DrugsPrednisolone/prednisone·Saruparib·Abiraterone

AstraZeneca

Phase 3

700

Barcelona, Girona, Madrid, Majadahonda, Málaga, Oviedo, Sabadell, Santander

2025-08-06

Recruiting

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

NCT07044336Endometrial Cancer, Malignant Solid Tumour

DrugsAdriamycin·Taxol·Doxorubicin·Paclitaxel

AstraZeneca

Phase 3

800

Badalona, Barcelona, Córdoba, El Palmar (Murcia), L'Hospitalet de Llobregat, Madrid, Málaga, Oviedo

2025-08-01

Recruiting

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

NCT07069712Gastroesophageal Adenocarcinoma

DrugsSonesitatug Vedotin·Calcium folinate·Rilvegostomig·Trastuzumab deruxtecan

AstraZeneca

Phase 2

100

Barcelona, Elche, Madrid, Málaga, Ourense, Oviedo, Santander, Valencia

2025-07-17

Active, closed

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With HeFH

NCT07000136Heterozygous Familial Hypercholesterolaemia

DrugAZD0780

AstraZeneca

Phase 3

473

A Coruña, Barcelona, Córdoba, Reus, Seville

2025-06-10

Recruiting

A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event

NCT07000357Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

15,100

A Coruña, Alicante, Barcelona, Cáceres, Huelva, Madrid, Málaga, Murcia

2025-06-04

Active, closed

A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event

NCT07000123Cardiovascular Disease

DrugAZD0780

AstraZeneca

Phase 3

3,103

A Coruña, Barcelona, Córdoba, Madrid, Santiago(A Coruña), Seville

2025-05-28

Recruiting

Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)

NCT06960577Urinary Bladder Neoplasms, Immune Checkpoint Inhibitors, Methotrexate, Vinblastine

DrugsVinblastine·Methotrexate·Doxorubicin·Durvalumab

AstraZeneca

Phase 2

150

Barcelona, Girona, Las Palmas de Gran Canaria, Lugo, Madrid, Santiago de Compostela

2025-05-15

Recruiting

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

NCT06921785Hepatocellular Carcinoma

DrugsRilvegostomig·Tremelimumab·Atezolizumab·Bevacizumab

AstraZeneca

Phase 3

1,220

Barcelona, Madrid, Santander

2025-05-06

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

NCT06868277Carcinoma, Non-Small Cell Lung

DrugsRilvegostomig·Keytruda·Pembrolizumab

AstraZeneca

Phase 3

830

Badajoz, Badalona, Barcelona, Castellon, Granada, Jaén, Lugo, Madrid

2025-04-10

Recruiting

Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment

NCT06750289Eosinophilic Asthma

AstraZeneca

Phase 3

400

Alcorcón, Alzira (Valencia), Badalona, Barakaldo, Barcelona, Burgos, Cáceres, Granada

2025-03-28

Recruiting

First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

NCT06795022Hepatocellular Carcinoma

AstraZeneca

Phase 1/2

304

Barcelona, Pamplona

2025-03-27

Recruiting

Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids

NCT06932263Asthma

DrugTozorakimab

AstraZeneca

Phase 2

540

Barcelona, Madrid, Málaga, Mérida, Patraix, Santander

2025-03-26

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

NCT06883305Chronic Obstructive Pulmonary Disease (COPD)

DrugTezepelumab

AstraZeneca

Phase 3

990

Barakaldo, Barcelona, Granada, Madrid, Málaga, Palma de Mallorca, Pamplona, Seville

2025-03-18

Recruiting

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

NCT06677060Heart Failure

DrugBaxdrostat/dapagliflozin

AstraZeneca

Phase 3

11,300

A Coruña, Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Málaga, Sant Joan Despí, Santiago(A Coruña)

2025-03-14

Recruiting

A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

NCT06792695Metastatic Colorectal Cancer

DrugsFOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)·Volrustomig·Bevacizumab

AstraZeneca

Phase 2

Barcelona, Madrid, Málaga, Pamplona, Santander, Valencia

2025-03-12

Active, closed

An Ophthalmic Safety Study in Patients With Breast Cancer

NCT06767462Ophthalmic Safety in Patients With Breast Cancer

AstraZeneca

Observational

160

Badalona, Barcelona, Girona, L'Hospitalet de Llobregat, Leganés, Madrid, Majadahonda, Salamanca

2025-03-05

Recruiting

A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer

NCT06764875HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

DrugsRilvegostomig·Trastuzumab deruxtecan·Trastuzumab·Adrucil

AstraZeneca

Phase 3

840

Badalona, Barcelona, Madrid, Ourense, Santander, Seville, Valencia

2025-03-01

Recruiting

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

NCT06651970Chronic Lymphocytic Leukaemia, Moderate to Severe Cardiac Impairment

DrugAcalabrutinib

AstraZeneca

Phase 4

Barcelona, Madrid, Seville

2025-02-04

Recruiting

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies

NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma

DrugsSurovatamig·Acalabrutinib·Vincristine·Doxorubicin

AstraZeneca

Phase 1/2

408

Barcelona, Madrid, Palma de Mallorca, Santiago de Compostela, Valencia

2025-01-30

Active, closed

A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain

NCT06764186Locally Advanced or Metastatic Breast Cancer

DrugsCapivasertib·Fulvestrant

AstraZeneca

Phase 3

101

Alicante, Barcelona, Bilbao (Vizcaya), Córdoba, Donostia / San Sebastian, El Palmar, Girona, Madrid

2025-01-07

Active, closed

A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain

NCT06746116Advanced or Recurrent Endometrial Cancer

DrugDurvalumab

AstraZeneca

Phase 3

A Coruña, Alicante, Barakaldo, Barcelona, Córdoba, El Palmar, Girona, L'Hospitalet de Llobregat

2024-12-30

Active, closed

A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab

NCT06706817Chronic Rhinosinusitis With Nasal Polyps

AstraZeneca

Phase 3

181

Barcelona, Cadiz, Madrid, Salamanca, Santiago de Compostela

2024-12-03

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC

NCT06627647Non-squamous Non-small Cell Lung Cancer

DrugsRilvegostomig·Pemetrexed·Keytruda·Cisplatin

AstraZeneca

Phase 3

1,160

Barcelona, Castellon, Las Palmas de Gran Canaria, Madrid, Majadahonda, Seville

2024-11-27

Recruiting

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

NCT06526793B-cell Non-Hodgkin Lymphoma, Follicular Lymphoma (FL), Large B-Cell Lymphoma (LBCL)

DrugSurovatamig

AstraZeneca

Phase 2

270

Barcelona, Madrid, Pozuelo de Alarcón

2024-11-27

Recruiting

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

NCT06692738Non-small Cell Lung Cancer

DrugsRilvegostomig·Nab-paclitaxel·Keytruda·Paclitaxel

AstraZeneca

Phase 3

1,160

Barcelona, Las Palmas de Gran Canaria, Lleida, Madrid, Majadahonda, Seville

2024-11-18

Recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT06417814Metastatic Non-small Cell Lung Cancer

DrugsTagrisso·Dato-DXd·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

744

A Coruña, Barakaldo, Barcelona, El Palmar, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga

2024-10-04

Active, closed

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT06473779Severe Asthma

AstraZeneca

Phase 3

310

Badalona(Barcelona), Barcelona, Lugo, Madrid

2024-09-30

Recruiting

A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

NCT05663515Pancreatic Cancer

DrugExenatide

AstraZeneca

Observational

24,000

Barcelona

2024-09-30

Recruiting

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

NCT06542250B-cell Malignancies

DrugAZD5492

AstraZeneca

Phase 1/2

174

Barcelona, L'Hospitalet de Llobregat, Madrid

2024-09-18

Active, closed

Phase IIa Study Evaluating AZD7798 in Crohn's Disease

NCT06450197Moderate to Severe Crohn's Disease

DrugAZD7798

AstraZeneca

Phase 2

120

Barcelona, Seville

2024-08-28

Active, closed

Volrustomig Priming Regimens Exploratory Phase II Platform Study

NCT06448754Non-small Cell Lung Cancer

DrugsVolrustomig·Ramucirumab·Pemetrexed·Paclitaxel

AstraZeneca

Phase 2

194

A Coruña, Alcorcón, Barcelona, Madrid, Málaga, Pamplona, Santander, Santiago de Compostela

2024-08-27

Recruiting

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357Biliary Tract Cancer

DrugsRilvegostomig·Trastuzumab deruxtecan·Durvalumab·Gemcitabine

AstraZeneca

Phase 3

620

Barcelona, Madrid, Málaga, Santander

2024-08-12

Recruiting

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

NCT06549595Untreated Follicular Lymphoma

DrugsSurovatamig·R-Chop

AstraZeneca

Phase 3

1,018

Barcelona, El Palmar, Girona, Las Palmas de Gran Canaria, Madrid, Oviedo, Pamplona, Santander

2024-08-07

Recruiting

Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer

NCT06380751Advanced Breast Cancer

DrugsSaruparib·Camizestrant·Exemestane·Anastrozole

AstraZeneca

Phase 3

788

A Coruña, Barcelona, Cáceres, Granada, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona

2024-08-01

Active, closed

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

NCT06015737Cutaneous Lupus Erythematosus

AstraZeneca

Phase 3

339

Barcelona, Castellon, Granada, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Majadahonda, Salamanca

2024-06-29

Recruiting

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis

NCT06465810Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR

AstraZeneca

Observational

1,850

Huelva, Bilbao, Las Palmas de Gran Canaria, Salamanca, Barcelona, Cataluna, Majadahonda, Islas Baleares

2024-06-25

Recruiting

A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

NCT06455449Polymyositis, Dermatomyositis

AstraZeneca

Phase 3

240

A Coruña, Barcelona, Córdoba, L'Hospitalet de Llobregat, Madrid, Sabadell, Valladolid

2024-06-20

Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

NCT06350097Non-small Cell Lung Cancer

DrugsDato-DXd·Osimertinib

AstraZeneca

Phase 3

582

A Coruña, Barcelona, Granada, Madrid, Majadahonda, Valencia

2024-04-29

Active, closed

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

NCT06194448Lung Cancer

DrugsTagrisso·Osimertinib·Pemetrexed·Paclitaxel

AstraZeneca

Phase 2

Barcelona, Donostia / San Sebastian, Granada, Madrid

2024-04-21

Recruiting

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

NCT06307652Heart Failure and Impaired Kidney Function

AstraZeneca

Phase 3

3,850

A Coruña, Barcelona, Lugo, Madrid, Majadahonda, Seville, Valencia

2024-04-12

Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

NCT06357533Non-Small Cell Lung Cancer

DrugsRilvegostomig·Dato-DXd·Keytruda·Pembrolizumab

AstraZeneca

Phase 3

675

Alicante, Barcelona, Jerez de la Frontera, Reus, Salamanca

2024-04-11

Active, closed

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

NCT06346392Gastric Cancer, Gastroesophageal Junction Cancer

DrugsSonesitatug Vedotin·Ramucirumab·Trifluridine/Tipiracil·Apatinib

AstraZeneca

Phase 3

594

Barcelona, Madrid, Ourense, Santander, Seville

2024-03-04

Active, closed

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)

NCT05925530Non-small Cell Lung Cancer

DrugDurvalumab

AstraZeneca

Phase 2

142

Barakaldo, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Valencia, Zaragoza

2024-02-22

Recruiting

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

NCT06283966COPD (Chronic Obstructive Pulmonary Disease)

AstraZeneca

Phase 3

5,250

Alicante, Badia Del Vallès, Barakaldo, Barcelona, Castro Urdiales, Córdoba, Granada, Madrid

2024-02-21

Recruiting

A Study of AZD3470, a PRMT5 Inhibitor, Given as Monotherapy and in Combination in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors

NCT06130553Advanced Solid Tumors That Are MTAP Deficient

DrugsAZD3470·Dato-DXd

AstraZeneca

Phase 1/2

334

Barcelona, Madrid

2024-01-18

Recruiting

AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

NCT06137118B-cell Acute Lymphoblastic Leukemia (B-ALL)

DrugSurovatamig

AstraZeneca

Phase 1/2

255

Barcelona, Madrid, Salamanca, Valencia

2023-12-29

Recruiting

A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy

NCT06129864Locally Advanced Head and Neck Squamous Cell Carcinoma

DrugVolrustomig

AstraZeneca

Phase 3

1,145

Badalona, Barcelona, Jaén, Madrid, Valencia

2023-12-14

Recruiting

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

NCT06219941Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma

DrugsL-leucovorin·Nanoliposomal Irinotecan·Onivyde·Sonesitatug Vedotin

AstraZeneca

Phase 2

226

Barcelona, Madrid

2023-12-13

Recruiting

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

NCT06188520ER+ HER2- Advanced Breast Cancer, High-grade Serous Ovarian Cancer (HGSOC)

DrugsCamizestrant·Abemaciclib·Ribociclib·Palbociclib

AstraZeneca

Phase 1/2

564

Barcelona, Pamplona, Valencia

2023-12-05

Active, closed

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)

NCT06109779Biliary Tract Cancer

DrugsGemcitabine/Cisplatin·Rilvegostomig·Teysuno·Capecitabine

AstraZeneca

Phase 3

760

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Santander

2023-12-04

Recruiting

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

NCT06103864Breast Cancer

DrugsDato-DXd·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 3

625

Barcelona, Granada, Hospitalet deLlobregat, Madrid, Pamplona, Santander

2023-11-23

Active, closed

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

NCT06120491Metastatic Castration-Sensitive Prostate Cancer

DrugsSaruparib·Zytiga·Xtandi·Abiraterone acetate

AstraZeneca

Phase 3

1,898

Barcelona, Córdoba, L'Hospitalet de Llobregat, Lugo, Madrid, Sabadell, Valencia

2023-11-21

Active, closed

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

NCT06112379Breast Cancer

DrugsDato-DXd·Epirubicin·Xeloda·Olaparib

AstraZeneca

Phase 3

1,902

Barcelona, Granada, Hospitalet deLlobregat, Madrid, Santiago de Compostela, Seville, Zaragoza

2023-11-14

Active, closed

MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

NCT06097728Unresectable Pleural Mesothelioma

DrugsVolrustomig·Yervoy·Paraplatin·Ipilimumab

AstraZeneca

Phase 3

863

Barakaldo, Barcelona, Madrid, Oviedo

2023-11-09

Active, closed

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)

NCT05925803Systemic Sclerosis, Scleroderma

AstraZeneca

Phase 3

314

A Coruña, Barcelona, Madrid, Málaga, Valencia

2023-11-08

Active, closed

A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.

NCT05984277Metastatic Non-small Cell Lung Cancer

DrugsVolrustomig·Pemetrexed·Paclitaxel·Carboplatin

AstraZeneca

Phase 3

895

Alicante, Barcelona, Bilbao (Vizcaya), Madrid, Málaga, Palma

2023-10-24

Active, closed

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

NCT05952557Breast Cancer, Early Breast Cancer

DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole

AstraZeneca

Phase 3

5,511

A Coruña, Albacete, Alicante, Badalona, Barakaldo, Barcelona, Burgos, Castellon

2023-10-05

Recruiting

Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)

NCT06079671Locally Advanced Cervical Cancer

DrugVolrustomig

AstraZeneca

Phase 3

800

A Coruña, Barcelona, Córdoba, Girona, Hospitalet deLlobregat, Madrid, Palma de Mallorca, Valencia

2023-09-22

Recruiting

A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma

NCT06023589Asthma

DrugTezepelumab

AstraZeneca

Phase 3

231

Badalona, Barcelona, Esplugues de Llobregat (Barc), Madrid, Sabadell, Valencia, Villarreal

2023-08-24

Recruiting

OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

NCT06355934ATTR Amyloidosis

AstraZeneca

Observational

52,121

A Coruña, Barcelona, Bilbao, El Palmar, Huelva, Las Palmas de Gran Canaria, Madrid, Majadahonda

2023-08-21

Active, closed

Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)

NCT05771480Biliary Tract Cancer

DrugsAlbumin-Bound Paclitaxel·Teysuno·Durvalumab·Oxaliplatin

AstraZeneca

Phase 3

142

Barcelona, Madrid, Pamplona, Seville

2023-08-16

Recruiting

OSIREAL - Osimertinib RWE on EGFRm NSCLC in Spain

NCT06068049Non-small Cell Lung Cancer

AstraZeneca

Observational

500

A Coruña, Alicante, Barcelona, C Rdoba, El Palmar, Girona, Granada, Jaén

2023-07-28

Active, closed

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)

NCT05883644Advanced Hepatocellular Carcinoma

DrugsTremelimumab·Durvalumab

AstraZeneca

Phase 3

111

Barcelona, Córdoba, Madrid, Pamplona

2023-06-27

Recruiting

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma

DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin

AstraZeneca

Phase 1/2

622

Barcelona, Madrid, Málaga

2023-06-05

Active, closed

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

NCT05775159Hepatocellular Carcinoma, Biliary Tract Cancer

DrugsVolrustomig·Rilvegostomig·Lenvatinib·Gemcitabine

AstraZeneca

Phase 2

294

Barcelona, Madrid, Pamplona

2023-04-24

Active, closed

A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma

NCT05692180Asthma

DrugBenralizumab

AstraZeneca

Phase 3

Badalona, Barcelona, Benalmádena, Esplugues de Llobregat

2023-04-05

Active, closed

A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

NCT05526755Stage II-IIIB Non-small Cell Lung Carcinoma

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 2

188

Badalona, Barcelona, Bilbao, Granada, L'Hospitalet de Llobregat, Madrid, Seville, Valencia

2023-03-06

Recruiting

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT05702229Gastric Cancer

DrugsSonesitatug Vedotin·Volrustomig·Xelox·Rilvegostomig

AstraZeneca

Phase 2

163

Barcelona, Elche(Alicante), L'Hospitalet de Llobregat, Madrid, Santander

2023-01-16

Active, closed

First in Human Study of AZD9592 in Solid Tumors

NCT05647122Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms

DrugsAZD9592·Osimertinib·Leucovorin·Adrucil

AstraZeneca

Phase 1

190

Barcelona, Madrid, Seville

2022-12-21

Recruiting

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

NCT05624450Viral Lung Infection and Acute Respiratory Failure

DrugTozorakimab

AstraZeneca

Phase 3

3,527

Barcelona, Madrid, Majadahonda, Málaga, Ourense, Palma de Mallorca, Pamplona, Santander

2022-12-13

Active, closed

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

NCT05629585Breast Cancer

DrugsDato-DXd·Xeloda·Durvalumab·Keytruda

AstraZeneca

Phase 3

1,174

Barcelona, Bilbao (Vizcaya), Elche(Alicante), Madrid, Málaga, Palma de Mallorca, Toledo, Valencia

2022-11-28

Active, closed

Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis

NCT05583227Eosinophilic Esophagitis

DrugTezepelumab

AstraZeneca

Phase 3

368

Barcelona, Madrid, Pamplona, Seville, Tomelloso

2022-11-10

Active, closed

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

NCT05450692Advanced or Metastatic Non-Small Cell Lung Cancer

DrugsCeralasertib·Durvalumab·Docetaxel

AstraZeneca

Phase 3

594

A Coruña, Barcelona, Castellon, Córdoba, Hospitalet deLlobregat, Madrid, Málaga, Ourense

2022-09-15

Active, closed

A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT05057494Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

DrugsAcalabrutinib·Obinutuzumab·Venetoclax

AstraZeneca

Phase 3

607

Barcelona, Palma de Mallorca

2022-09-12

Recruiting

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

NCT05489211Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer, Ovarian Cancer

DrugsPrednisone/Prednisolone·Volrustomig·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 2

454

Barcelona, Córdoba, Madrid, Málaga, Pamplona, Seville

2022-09-06

Active, closed

A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition

NCT05061134Melanoma

DrugsCeralasertib·Durvalumab

AstraZeneca

Phase 2

194

Barcelona, Madrid, Málaga, Pamplona, Pozuelo de Alarcón

2022-08-11

Active, closed

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

NCT05261399Carcinoma, Non-Small-Cell Lung

DrugsSavolitinib·Tagrisso·Osimertinib·Pemetrexed

AstraZeneca

Phase 3

341

Badajoz, Badalona, Barcelona, Córdoba, Girona, Madrid, Majadahonda, Málaga

2022-08-03

Recruiting

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

NCT05417594Advanced Solid Malignancies

DrugsPalacaparib·Dato-DXd·Trastuzumab deruxtecan·Temozolomide

AstraZeneca

Phase 1/2

695

A Coruña, Barcelona, Málaga, Pozuelo de Alarcón, Sant Cugat del Vallès, Seville

2022-06-24

Active, closed

PASS of Paediatric Patients Initiating Selumetinib

NCT05388370Neurofibromatosis Type 1

AstraZeneca

Observational

124

Barcelona, Madrid, Málaga, Santiago de Compostela, Seville

2022-05-23

Active, closed

A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)

NCT05374512Breast Cancer

DrugsEribulin·Dato-DXd·Nab-paclitaxel·Capecitabine

AstraZeneca

Phase 3

644

Barcelona, Granada, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Santiago de Compostela, Seville

2022-05-16

By invitation

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab

NCT05303532Cancer

DrugDurvalumab

AstraZeneca

Phase 3

214

Barcelona, Girona, Madrid, Marbella, Santiago de Compostela, Valencia

2022-04-19

Recruiting

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

NCT05061550Non-small Cell Lung Cancer

DrugsAZD0171·Pemetrexed/Cisplatin·Pemetrexed/Carboplatin·Monalizumab

AstraZeneca

Phase 2

630

A Coruña, Alicante, Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Reus

2022-04-14

Active, closed

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

NCT05301842Hepatocellular Carcinoma

DrugsTremelimumab·Lenvatinib·Durvalumab

AstraZeneca

Phase 3

760

Barcelona, Córdoba, Donostia / San Sebastian, Madrid

2022-03-28

Active, closed

Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05348577Prostate Cancer

DrugsCapivasertib·Docetaxel

AstraZeneca

Phase 3

1,035

Barcelona, Córdoba, Lugo, Madrid, Málaga, Sabadell, Seville

2022-03-25

Active, closed

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

NCT05120349Non-Small Cell Lung Cancer

DrugsTagrisso·Osimertinib

AstraZeneca

Phase 3

390

Barcelona, Málaga, Valencia, Vigo, Zaragoza

2022-02-21

Active, closed

A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer

NCT05221840Non-Small Cell Lung Cancer

DrugsMonalizumab·Oleclumab·Durvalumab

AstraZeneca

Phase 3

1,051

Barcelona, Granada, Madrid, Santiago de Compostela, Valencia

2022-02-07

Active, closed

Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN

NCT05309668Neurofibromatosis Type 1

DrugSelumetinib

AstraZeneca

Phase 1/2

Barcelona, Madrid

2022-01-21

Active, closed

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

NCT04999969Locally Advanced or Metastatic Solid Tumours

DrugsAZD0171·Durvalumab·Nab-paclitaxel·Gemcitabine

AstraZeneca

Phase 2

126

Badalona, Barcelona, Madrid, Majadahonda, Pamplona

2021-12-10

Active, closed

Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC

NCT05043090Papillary Renal Cell Carcinoma

DrugsSavolitinib·Sunitinib·Durvalumab

AstraZeneca

Phase 3

148

A Coruña, Barcelona, Córdoba, Madrid, Majadahonda, Málaga, Pamplona, Seville

2021-10-28

Active, closed

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer

DrugsHerzuma·Perjeta·Herceptin·Adriamycin

AstraZeneca

Phase 3

927

Barcelona, Madrid, Seville, Vigo

2021-10-25

Active, closed

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

NCT05104866Breast Cancer

DrugsEribulin·Dato-DXd·Vinorelbine·Capecitabine

AstraZeneca

Phase 3

732

A Coruña, Barcelona, Bilbao (Vizcaya), Huelva, L'Hospitalet de Llobregat, Madrid, Málaga, Seville

2021-10-18

Recruiting

A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies

NCT05123482Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer, Endometrial Cancer

DrugsPalacaparib·Saruparib·Rilvegostomig

AstraZeneca

Phase 1/2

460

Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona

2021-10-18

Active, closed

A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer

NCT04931654Carcinoma, Non-Small-Cell Lung, Gastric Cancer, Gastroesophageal Junction Cancer

DrugSabestomig

AstraZeneca

Phase 1/2

136

Barcelona, Madrid

2021-09-28

Active, closed

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC

NCT04995523Non-Small-Cell Lung Carcinoma

DrugRilvegostomig

AstraZeneca

Phase 1/2

212

Barcelona, Madrid

2021-09-14

Active, closed

A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)

NCT04765059Non-small Cell Lung Cancer

DrugCarboplatin

AstraZeneca

Phase 3

Alicante, Barcelona, Córdoba, León, Madrid, Málaga, Murcia, Oviedo

2021-09-12

Active, closed

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

NCT04960709Muscle Invasive Bladder Cancer

DrugsEnfortumab Vedotin·Tremelimumab·Durvalumab

AstraZeneca

Phase 3

712

Barcelona, L'Hospitalet de Llobregat, Las Palmas de Gran Canaria, Madrid, Pamplona, Seville

2021-08-05

Active, closed

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

NCT05101148Neurofibromatosis Type 1

DrugSelumetinib

AstraZeneca

Phase 1

Barcelona, Madrid

2021-07-21

Active, closed

Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)

NCT04964934ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Abemaciclib·Ribociclib

AstraZeneca

Phase 3

315

A Coruña, Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Murcia, Sant Joan Despí

2021-06-30

Active, closed

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

NCT04739761Breast Cancer

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 3

506

Barcelona, Bilbao (Vizcaya), Granada, Madrid, Salamanca, Santander, Santiago de Compostela-Coruña, Seville

2021-06-22

Active, closed

Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus

NCT04877691Systemic Lupus Erythematosus

DrugAnifrolumab

AstraZeneca

Phase 3

367

Barcelona, Madrid, Santiago de Compostela, Seville, Valencia

2021-06-08

Active, closed

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)

NCT04862663Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Abemaciclib·Ribociclib·Palbociclib

AstraZeneca

Phase 3

893

Barcelona, Granada, Lleida, Madrid, Málaga, Pamplona, Santiago de Compostela

2021-05-10

Active, closed

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

NCT04784715Breast Cancer; HER2-positive; Metastatic

DrugsPertuzumab·Trastuzumab deruxtecan·Trastuzumab

AstraZeneca

Phase 3

1,157

Alicante, Barcelona, Madrid, Majadahonda, Seville

2021-04-26

Active, closed

Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

NCT04612751Advanced or Metastatic NSCLC

DrugsSabestomig·Volrustomig·Rilvegostomig·Dato-DXd

AstraZeneca

Phase 1

155

A Coruña, Badalona, Barcelona, Madrid, Seville

2021-02-02

Active, closed

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

NCT04711252ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Anastrozole·Palbociclib

AstraZeneca

Phase 3

1,371

Barcelona, Jaén, Lleida, Madrid, Málaga, Pamplona, Santander, Seville

2021-01-28

Active, closed

A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations

NCT04639219Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 2

102

Barcelona, Madrid, Pamplona, Seville

2020-12-30

Active, closed

A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer

NCT04538742Metastatic Breast Cancer

DrugsTucatinib·Pertuzumab·Trastuzumab deruxtecan·Durvalumab

AstraZeneca

Phase 1/2

245

Barcelona, L'Hospitalet de Llobregat, Madrid, Seville

2020-12-28

Active, closed

A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer

NCT04351555Non-Small Cell Lung Cancer

DrugsTagrisso·Osimertinib·Pemetrexed·Cisplatin

AstraZeneca

Phase 3

358

Barcelona, Madrid, Majadahonda, Málaga

2020-12-16

Active, closed

Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

NCT04592913Gastrointestinal Neoplasms, Esophagogastric Junction

DrugDurvalumab

AstraZeneca

Phase 3

957

Barcelona, Madrid, Málaga, Ourense, Santander, Seville, Valencia

2020-11-17

Active, closed

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

NCT04644068Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer

DrugsSaruparib·Camizestrant·Dato-DXd·Trastuzumab deruxtecan

AstraZeneca

Phase 1/2

702

Barcelona, Madrid, Málaga, Pozuelo de Alarcón, Seville

2020-11-12

Active, closed

Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC

NCT04550260Esophageal Squamous Cell Carcinoma

DrugsFluorouracil·Durvalumab·Capecitabine·Cisplatin

AstraZeneca

Phase 3

640

Barcelona, Córdoba, Madrid, Pamplona, Santander, Zaragoza

2020-10-19

Active, closed

Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

NCT04590963Squamous Cell Carcinoma of the Head and Neck

DrugsMonalizumab·Erbitux·Cetuximab

AstraZeneca

Phase 3

370

Barcelona, Madrid, Valencia

2020-10-02

Active, closed

A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors

NCT04482309Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer, Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer

DrugTrastuzumab deruxtecan

AstraZeneca

Phase 2

477

Barcelona, Córdoba, Madrid, Valencia

2020-08-18

Active, closed

Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib

NCT04421963Ovarian Cancer, Breast Cancer

DrugOlaparib

AstraZeneca

Phase 3

185

Badalona, Barcelona, Córdoba, Donostia / San Sebastian, Granada, Madrid, Pamplona, Valencia

2020-08-04

Active, closed

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer

NCT04494425Advanced or Metastatic Breast Cancer

DrugsTrastuzumab deruxtecan·Nab-paclitaxel·Capecitabine·Paclitaxel

AstraZeneca

Phase 3

866

A Coruña, Barcelona, Córdoba, El Palmar, Madrid, San Sebastián, Seville, Valencia

2020-07-24

Active, closed

Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency

NCT04493853Hormone-Sensitive Prostate Cancer

DrugsZytiga·Capivasertib·Abiraterone acetate

AstraZeneca

Phase 3

1,012

Badalona (Barcelona), Barcelona, Las Palmas de Gran Canaria, Madrid, Oviedo, Santander, Seville

2020-07-13

Active, closed

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)

NCT04379596Gastric Cancer

DrugsVolrustomig·Rilvegostomig·Trastuzumab deruxtecan·Fluorouracil

AstraZeneca

Phase 2

452

Barcelona, Madrid, Santander, Seville

2020-06-03

Active, closed

Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer

NCT04269200Endometrial Neoplasms

DrugsOlaparib·Durvalumab·Paclitaxel·Carboplatin

AstraZeneca

Phase 3

805

Barcelona, El Palmar, Girona, Jaén, Madrid, Mallorca

2020-05-05

Active, closed

A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer

NCT04214288Advanced ER-Positive HER2-Negative Breast Cancer

DrugsCamizestrant·Fulvestrant

AstraZeneca

Phase 2

240

Barcelona, Madrid, Seville, Zaragoza

2020-04-22

Active, closed

Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

NCT04305496Locally Advanced (Inoperable) or Metastatic Breast Cancer

DrugsCapivasertib·Fulvestrant

AstraZeneca

Phase 3

818

A Coruña, Barcelona, Córdoba, Hosp de Llobregat(Barcelona), Jaén, La Laguna (Tenerife), Lleida, Madrid

2020-04-16

Active, closed

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

NCT03944772Non-Small Cell Lung Cancer

DrugsNecitumumab·Gefitinib·Savolitinib·Selpercatinib

AstraZeneca

Phase 2

247

A Coruña, Barcelona, Madrid, Seville

2019-06-25

Active, closed

Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

NCT03997123Triple Negative Breast Neoplasms

DrugsCapivasertib·Paclitaxel

AstraZeneca

Phase 3

923

Badalona, Barcelona, Hospitalet deLlobregat, Jaén, Madrid, Málaga, Seville, Valencia

2019-06-25

Active, closed

Durvalumab and Tremelimumab for Pediatric Malignancies

NCT03837899Pediatric Cancer, Solid Tumor Pediatric, Hematological Malignancies

DrugDurvalumab

AstraZeneca

Phase 1/2

Barcelona, Madrid

2019-03-07

Active, closed

Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation

NCT03833154Carcinoma, Non-Small-Cell Lung

DrugDurvalumab

AstraZeneca

Phase 3

724

Badajoz, Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, San Sebastián, Santiago de Compostela, Seville

2019-03-06

Active, closed

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC

NCT03819465Metastatic Non-Small Cell Lung Cancer (NSCLC)

DrugsDanvatirsen·Oleclumab·Volrustomig·Rilvegostomig

AstraZeneca

Phase 1

175

Barcelona, Madrid, Seville

2018-12-27

Active, closed

A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

NCT03800134Non-Small Cell Lung Cancer

DrugsDurvalumab·Pemetrexed·Gemcitabine·Paclitaxel

AstraZeneca

Phase 3

825

Alicante, Barcelona, Donostia / San Sebastian, Madrid, Málaga, Oviedo, Pamplona, Santiago de Compostela (A Coruña)

2018-12-06

Active, closed

Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

NCT03732677Muscle Invasive Bladder Cancer

DrugsDurvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,063

Badalona, Barcelona, Córdoba, Las Palmas de Gran Canaria, Madrid, Santander, Seville

2018-11-16

Active, closed

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

NCT03732820Metastatic Castration-resistant Prostate Cancer

DrugsZytiga·Abiraterone acetate·Olaparib

AstraZeneca

Phase 3

895

Barcelona, Girona, Madrid, Málaga, Seville

2018-10-31

Active, closed

Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.

NCT03616587ER+ HER2- Advanced Breast Cancer

DrugCamizestrant

AstraZeneca

Phase 1

396

Barcelona, Madrid, Seville, Valencia

2018-10-11

Active, closed

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy

NCT03703297Small Cell Lung Cancer

DrugsTremelimumab·Durvalumab

AstraZeneca

Phase 3

730

Barcelona, Madrid, Oviedo, Seville, Valencia, Zaragoza

2018-09-27

Active, closed

Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer

NCT03682068Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer

DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,246

Barcelona, Lugo, Madrid, Málaga, Santander, Seville

2018-09-27

Active, closed

A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)

NCT03521154Non Small Cell Lung Cancer (Stage III)

DrugOsimertinib

AstraZeneca

Phase 3

216

Barcelona, Madrid, Málaga, San Sebastián, Seville, Valencia

2018-07-19

Active, closed

Assessment of Efficacy and Safety of Durvalumab Plus BCG Compared to the Standard Therapy With BCG in Non-muscle Invasive Bladder Cancer

NCT03528694Non-muscle-invasive Bladder Cancer

DrugsBacillus Calmette-Guerin·Durvalumab

AstraZeneca

Phase 3

1,018

Badajoz, Barcelona, Elche(Alicante), Madrid, Málaga, Oviedo, Pamplona, Pozuelo de Alarcón

2018-05-14

Active, closed

A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

NCT03459846Urinary Bladder Neoplasms

DrugsOlaparib·Durvalumab

AstraZeneca

Phase 2

154

Barcelona, Madrid, Málaga, Santiago de Compostela

2018-03-16

Active, closed

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

NCT03330847Metastatic Triple Negative Breast Cancer

DrugCeralasertib

AstraZeneca

Phase 2

273

Barcelona, Cáceres, Madrid, Palma de Mallorca, San Sebastián, Sant Cugat del Vallès, Seville, Valencia

2018-03-07

Active, closed

Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy

NCT03334617Non-Small Cell Lung Cancer

DrugsDanvatirsen·Vistusertib·Cediranib Maleate·Ceralasertib

AstraZeneca

Phase 2

528

Barcelona, Madrid, Seville

2017-12-18

Active, closed

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

NCT03298451Hepatocellular Carcinoma

DrugsSorafenib·Tremelimumab·Durvalumab

AstraZeneca

Phase 3

1,324

Barcelona, Madrid, Oviedo, Pamplona Madrid, Santander

2017-10-11

Active, closed

Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)

NCT03043872Small Cell Lung Carcinoma Extensive Disease

DrugsTremelimumab·Etoposide·Durvalumab·Cisplatin

AstraZeneca

Phase 3

987

A Coruña, Badajoz, Badalona, Barcelona, Madrid, Santander, Valencia, Zaragoza

2017-03-27

Active, closed

Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder Cancer

NCT02546661Muscle Invasive Bladder Cancer

DrugsDanvatirsen·Fexagratinib·Vistusertib·Adavosertib

AstraZeneca

Phase 1

117

Badalona, Barcelona, Madrid

2016-12-28

Active, closed

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

NCT02516241Urothelial Cancer

DrugsTremelimumab·Durvalumab·Gemcitabine·Cisplatin

AstraZeneca

Phase 3

1,126

Badajoz, Badalona, Barcelona, Elche(Alicante), Madrid, Pozuelo de Alarcón, Santiago de Compostela, Seville

2015-11-02

Active, closed

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.

NCT02511106Stage IB-IIIA Non-small Cell Lung Carcinoma

DrugOsimertinib

AstraZeneca

Phase 3

682

A Coruña, Barcelona, Donostia / San Sebastian, Elche, Las Palmas de Gran Canaria, Madrid, Majadahonda, Málaga

2015-10-21

Active, closed

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

NCT02453282Non-Small-Cell Lung Carcinoma NSCLC

DrugsTremelimumab·Durvalumab·Pemetrexed·Gemcitabine

AstraZeneca

Phase 3

1,118

A Coruña, Alicante, Barcelona, Girona, Jaén, León, Madrid, Majadahonda

2015-07-21

Active, closed

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

NCT02032823Breast Cancer

DrugOlaparib

AstraZeneca

Phase 3

1,837

A Coruña, Ávila, Badajoz, Badalona, Barcelona, Castellon, Cáceres, Córdoba

2014-04-22

Active, closed

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

NCT01933932Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

DrugsPegylated G-CSF·Pegfilgrastim·Selumetinib·Docetaxel

AstraZeneca

Phase 3

510

Barcelona, Madrid, Málaga, Seville, Vigo(Pontevedra), Zaragoza

2013-09-25

Active, closed

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy

DrugOlaparib

AstraZeneca

Phase 3

327

Barcelona, Córdoba, Girona, Madrid, Pamplona, Valencia

2013-09-03

Active, closed

Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.

NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation

DrugOlaparib

AstraZeneca

Phase 3

450

Barcelona, Córdoba, Hospitalet deLlobregat(Barcelo, Madrid, Valencia

2013-08-26

Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 October 2026. https://priyalifescience.com/clinical-trials-spain/city/barcelona

Query this register directly

GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,875 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 188 of those studies with a site in Barcelona that also match the filters currently applied.

How many clinical trials are recruiting in Barcelona?

88 of the 188 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 1 have not yet opened recruitment, 98 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Barcelona), 188 studies
Phase	Studies	Recruiting	Share
Phase 3	115	46	61.2%
Phase 2	33	16	17.6%
Phase 1/2	21	15	11.2%
Phase 1	11	5	5.9%
Observational	7	5	3.7%
Phase 4	1	1	0.5%

Most active sponsors

Lead sponsors with the most studies (Barcelona)
Lead sponsor	Studies	Recruiting
AstraZeneca	188	88

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.